Company Overview - Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics to treat various human diseases [3] - The company emphasizes the relationship between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [3] - Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is advancing its product candidates through clinical development as standalone therapies and in combination with other proprietary antibodies [3] Upcoming Financial Results and Updates - Compass Therapeutics will release its financial results for the quarter ended June 30, 2025, and provide updates on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726 on August 11, 2025, at 8:00 AM ET [1] - A webcast and conference call will be held to discuss these updates, with a replay available for 90 days on the company's Events page [2]

Core Viewpoint - MacroGenics, Inc. is set to present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, highlighting its focus on innovative antibody-based therapeutics for cancer treatment [1]. Company Overview - MacroGenics is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing monoclonal antibody-based therapeutics specifically for cancer treatment [3]. - The company utilizes a proprietary suite of next-generation antibody-based technology platforms, which are applicable across various therapeutic domains, to generate its pipeline of product candidates [3]. - MacroGenics has established several strategic collaborations with global pharmaceutical and biotechnology companies, leveraging its technology platforms and protein engineering expertise to create promising product candidates [3]. Event Information - The presentation at the Goldman Sachs conference will take place at 8:00 am ET in Miami, FL, and will be accessible via a webcast on the company's Investor Relations website [1][2]. - An archived replay of the webcast will be available on the company's website for 30 days following the event [2].

Core Viewpoint - MacroGenics, Inc. is advancing its clinical pipeline, particularly with the initiation of the Phase 2 LINNET study for lorigerlimab, targeting unmet needs in ovarian and gynecologic cancers, while also reporting financial results for Q1 2025 [1][2]. Clinical Development Updates - The first patient has been dosed in the LINNET Phase 2 study of lorigerlimab for platinum-resistant ovarian cancer and clear cell gynecologic cancer, with a focus on addressing significant unmet needs [2][7]. - The LORIKEET Phase 2 trial, involving 150 patients, is ongoing to evaluate lorigerlimab in combination with docetaxel for metastatic castration-resistant prostate cancer (mCRPC), with results expected in the second half of 2025 [6][7]. - MacroGenics is developing three antibody-drug conjugates (ADCs) in collaboration with Synaffix, including MGC026, MGC028, and MGC030, targeting various solid tumors [4][6]. Financial Performance - Total revenue for Q1 2025 was $13.2 million, an increase from $9.1 million in Q1 2024, primarily due to collaborative agreements and contract manufacturing [8][13]. - Research and development expenses decreased to $39.7 million in Q1 2025 from $46.0 million in Q1 2024, while selling, general and administrative expenses also fell to $10.7 million from $14.7 million [8][13]. - The net loss for Q1 2025 was $41.0 million, compared to a net loss of $52.2 million in Q1 2024, indicating improved financial performance [8][13]. Cash Position and Guidance - As of March 31, 2025, MacroGenics had cash, cash equivalents, and marketable securities totaling $154.1 million, down from $201.7 million at the end of 2024, which supports operations into the second half of 2026 [8][11]. - The company plans to implement cost-saving measures to extend its financial runway while continuing to progress its clinical pipeline [8][11].

Core Insights - Compass Therapeutics presented promising preclinical data on CTX-471, a CD137 agonist antibody, at the AACR Annual Meeting, indicating enhanced efficacy in models of immune checkpoint failure through simultaneous blockade of neo-angiogenesis [1][2][3] Company Overview - Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology, with a scientific emphasis on the interplay between angiogenesis, the immune system, and tumor growth [10] Product Development - CTX-471 is currently in a Phase 1b clinical trial for patients with solid tumors that have progressed after at least three months on approved PD-1 or PD-L1 inhibitors, showing partial responses in melanoma, small cell lung cancer, and mesothelioma [5][6] - The combination of CTX-471 with tovecimig, an investigational bispecific antibody targeting DLL4 and VEGF-A, demonstrated significant anti-tumor activity in resistant murine models, suggesting potential clinical benefits for patients who have failed checkpoint inhibitors [6][9] Mechanism of Action - The combination therapy of CTX-471 and tovecimig enhances innate and adaptive anti-tumor immunity, leading to increased tumor cell killing and improved interferon signaling, which may provide therapeutic advantages in previously resistant cancer types [3][6] Clinical Trials - Tovecimig is being evaluated in the ongoing Phase 2/3 trial (COMPANION-002) in combination with paclitaxel for patients with advanced metastatic or recurrent biliary tract cancers, showing promise in heavily pre-treated patients resistant to anti-VEGF therapies [9]